(Q38578686)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Myeloid-derived suppressor cells in B cell malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Mehdi Yousefi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Ghasem Ghalamfarsa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Farhad Jadidi-Niaragh

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

Mousa Mohammadnia-Afrouzi

23 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Enayat Anvari

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Hadi Hasannia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sanam Sadreddini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

2 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

7339-7353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s13277-015-4004-z

23 February 2020

exact match

0 references

cites work

Haematological malignancies: at the forefront of immunotherapeutic innovation

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The role of natural killer T cells in B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Modulation of CD8(+) T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cell heterogeneity and subset definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Complexity and challenges in defining myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Signaling pathways involved in MDSC regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

High-efficiency induction of neural conversion in human ESCs and human induced pluripotent stem cells with a single chemical inhibitor of transforming growth factor beta superfamily receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Regulation of granulocyte colony-stimulating factor gene expression by interleukin-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Notch signaling induces multilineage myeloid differentiation and up-regulates PU.1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Subsets, expansion and activation of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

ADAM10 overexpression shifts lympho- and myelopoiesis by dysregulating site 2/site 3 cleavage products of Notch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells: Cellular missiles to target tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

L-arginine availability regulates T-lymphocyte cell-cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Inhibition of MHC II gene transcription by nitric oxide and antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Transport of cystine and cysteine in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

L-arginine metabolism in myeloid cells controls T-lymphocyte functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Role of immature myeloid Gr-1+ cells in the development of antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Novel therapeutic strategies for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Functional analyses of recombinant mouse hepcidin-1 in cell culture and animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Impact of hepcidin antimicrobial peptide on iron overload in tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Immune monitoring using the predictive power of immune profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Inhibition of B Lymphopoiesis by Adipocytes and IL-1-Producing Myeloid-Derived Suppressor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4004-Z

Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin

21 January 2018

1 reference

12 December 2020

Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

1 reference

12 December 2020

Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells

1 reference

12 December 2020

Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy

1 reference

12 December 2020

Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease

1 reference

12 December 2020

STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion

1 reference

12 December 2020

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

1 reference

12 December 2020

Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells

1 reference

12 December 2020

Expression of an innate immune element (mouse hepcidin-1) in baculovirus expression system and the comparison of its function with synthetic human hepcidin-25.

1 reference

12 December 2020

Selective Involvement of the Checkpoint Regulator VISTA in Suppression of B-Cell, but Not T-Cell, Responsiveness by Monocytic Myeloid-Derived Suppressor Cells from Mice Infected with an Immunodeficiency-Causing Retrovirus

1 reference

12 December 2020

Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors

1 reference

12 December 2020

Novel targeted therapies in diffuse large B-cell lymphoma

1 reference

12 December 2020

Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family

1 reference

12 December 2020

The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma

1 reference

12 December 2020

Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma

1 reference

12 December 2020

Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow

1 reference

12 December 2020

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

1 reference

12 December 2020

Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation

1 reference

12 December 2020

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells.

1 reference

12 December 2020

Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets

1 reference

12 December 2020

Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

1 reference

12 December 2020

Activation of vascular endothelial growth factor receptor-2 in bone marrow leads to accumulation of myeloid cells: role of granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression

1 reference

12 December 2020

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

1 reference

12 December 2020

Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma

1 reference

12 December 2020

CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia

1 reference

12 December 2020

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma

1 reference

12 December 2020

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

1 reference

12 December 2020

10.1007/S13277-015-4004-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

23 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26330296%20AND%20SRC:MED&resulttype=core&format=json